Developer docs
API playgroundTry for free, no card

Search company profiles

Qlife

Full company profile

uuid0003coe

Namestring
Qlife
Legal namestring
Qlife Holding AB
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish-incorporated medical technology company that develops and markets the Egoo.Health platform — a modular, decentralized blood biomarker testing system consisting of the Egoo Q300 portable reader, swap-in test cartridges (HbA1c for diabetes management, PHE for phenylketonuria monitoring, hormone panels for women's health), and the Egoo.AI software module that delivers text-based personalized health insights to patients and clinicians. The platform is designed to deliver clinical-grade precision outside central laboratories, with the HbA1c test achieving a coefficient of variation below 3% and the PHE test demonstrating high concordance with Dry Blood Spot reference methods in the Birmingham Women's and Children's NHS Foundation Trust clinical trial.

Qlife operates through its wholly-owned Danish subsidiary Egoo.Health ApS and serves three primary customer segments: healthcare providers and institutions (hospitals, NHS trusts), pharmaceutical and IVD companies (via feasibility and licensing deals), and pharmacies and retail health providers (via a Nordic pilot). The business model is multi-stream and pre-commercial at scale: direct sales of Egoo hardware and consumable cartridges, a 20% royalty on net sales of Egoo products in China where Hipro Biotechnology owns manufacturing, regulatory, and commercialization, exclusive EU/US distribution rights for Hipro's FDA-approved HbA1c test under a 20-year agreement, and non-dilutive feasibility study funding from global pharma partners. Reported revenue remains minimal — kSEK 21 in Q1 2026 against an EBITDA loss of kSEK -5,502 — consistent with a platform still in regulatory, clinical-validation, and partnership-build phases.

Short descriptiontext

Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish medical technology company that develops the Egoo.Health platform — modular point-of-care blood biomarker testing devices and cartridges (HbA1c, PHE, hormones) with AI-driven insights — serving hospitals, pharmacies, and pharmaceutical partners across Europe, the US, and China via Hipro Biotechnology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVærløse, Denmark
HQ citystring
Værløse
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
home diagnostics, point-of-care testing, biomarker analysis, decentralized diagnostics, clinical blood testing
Industry6 codes
PRIMARYHLALAFAL
Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAFAA
Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAPAA
Remote Patient Monitoring (RPM) Platforms & Services
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALABAF
Chronic Care & Remote Patient Monitoring (RPM) Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Diagnostics / Home Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Egoo Platform Product Sales
TypeHardware Sales
Description

Direct sales of Egoo.Health testing devices and consumable cartridges to healthcare providers, pharmacies, and consumers for home biomarker testing. Revenue generated from hardware sales and recurring consumable revenue in markets where regulatory approvals are in place.

news.cision.com
2Licensing Royalties (China)
TypeLicensing Royalties
Description

Qlife receives a 20% royalty on net sales generated from Egoo products in China, where Hipro assumes full responsibility for development, regulatory approvals, manufacturing, and commercialization. This provides an asset-light revenue stream with no capital expenditure requirements.

news.cision.com
3Distribution Revenue (EU/US - Hipro Products)
TypeSubscription Recurring
Description

Exclusive right to sell and distribute Hipro Biotechnology's products (including FDA-approved HbA1c test) in EU and US markets under a 20-year commercial agreement with automatic renewal. Qlife markets and distributes Hipro products integrated with or alongside the Egoo platform.

news.cision.com
4Feasibility Study Funding
TypeProfessional Services
Description

Fully funded feasibility agreements with global pharmaceutical companies to evaluate specific biomarker applications on the Egoo Health platform for therapeutic use cases. Funded entirely by the pharma partner, representing non-dilutive revenue for R&D activities.

qlifeholding.com
5Partnership and Licensing Deals
TypeLicensing Royalties
Description

Revenue from co-development and licensing arrangements with global IVD and pharmaceutical partners. Includes potential milestone payments, development fees, and long-term supply agreements as partnerships progress from feasibility to commercialization.

news.cision.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Rights Issue 2026 — SEK 2.0 per share
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Up to 15,679,521 new shares at SEK 2.0 per share, raising approximately SEK 31.4 million. Guaranteed to approximately 82.9% through subscription commitments and guarantee agreements.

qlifeholding.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Egoo.Health
Description

Medical technology platform for clinical-grade home diagnostics enabling biomarker testing at home

qlifeholding.com
+5 more records
Core offering1 text field

Qlife develops and markets the Egoo.Health platform, a modular, decentralized blood biomarker testing system that enables clinical-grade diagnostics at home. The platform combines the portable Egoo Q300 analyzer with cartridge-based assays (HbA1c for diabetes management, PHE for phenylketonuria monitoring, and women's hormone panels) and AI-driven personalized insights delivered through device-to-cloud connectivity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • HbA1c coefficient of variation below 3% — best-in-class precision for home-use diabetes testing
+4 more records
Product overview1 text field

Qlife develops and markets the Egoo.Health medical technology platform for clinical-grade home diagnostics. The platform architecture consists of the Egoo Q300 hardware device supporting multiple test cartridges/modules including the Egoo HbA1c (diabetes management), Egoo PHE System (phenylketonuria monitoring), Women's Health Platform (hormone testing), and the Egoo.AI module for AI-driven personalized insights. The modular platform enables decentralized biomarker testing at home with accuracy comparable to central laboratory testing.

Product and service6 records
1Egoo.Health Platform
CategoryMedical diagnostics platform
Description

Clinical-grade medical technology platform for accurate biomarker testing at home. Uses a modular system that measures and analyses patient blood samples, enabling decentralized diagnostics for healthcare providers, pharmacies, pharma partners, and consumers.

2Egoo Q300 Device
CategoryDiagnostic hardware device
Description

Portable blood testing device with AI integration, device-to-cloud connectivity, and support for multiple biomarker cartridge tests. Designed for clinical-grade accuracy at home and in pharmacy settings.

3Egoo HbA1c Blood Test
CategoryDiagnostic test cartridge
Description

Home-use HbA1c test cartridge for diabetes management achieving best-in-class precision with coefficient of variation below 3%. FDA-approved for the US market via the Hipro partnership.

4Egoo PHE System
CategoryDiagnostic test cartridge
Description

Home testing system for Phenylketonuria (PKU) monitoring in children and adolescents. Validated through Birmingham Women's and Children's NHS Foundation Trust clinical trial; submitted for European IVDR regulatory approval.

5Women's Health Platform
CategoryConsumer health testing
Description

Hormone testing platform with AI-driven personalized insights focused on women's reproductive and hormonal health, enabling proactive self-managed health monitoring at home.

6Egoo.AI
CategoryAI-driven health insights
Description

AI-driven personalized health insights module integrated into the Egoo Health platform, providing customized health recommendations and chronic disease management insights based on biomarker test results.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Qlife entered a fully funded feasibility agreement with a global pharmaceutical company to evaluate a specific biomarker application on Egoo Health related to a therapeutic use case. The feasibility study is entirely funded by the pharma partner and is designed to answer technical and integration questions required to move into a long-term development and supply collaboration. The partner remains undisclosed.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Exclusive 20-year commercial agreement (with automatic renewal options) granting Qlife exclusive rights to distribute Hipro's products in the EU and US markets. Hipro has FDA approval for its HbA1c test (November 2024). The agreement includes integration of Hipro's FDA-approved HbA1c test with Qlife's Egoo platform, aiming to develop decentralized healthcare solutions. Separately, Qlife and Hipro pursued a reverse takeover (Nasdaq rejected the 'Red Chip' structure in November 2025; alternative structures being explored; LOI extended to December 31, 2026).

3Beijing Tsinghua Changgung Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-12
Description

Collaboration led by Hipro Biotechnology in China for an AI-driven personalized diabetes management project. Egoo Health blood testing platform is used for chronic disease management of diabetes and MASLD (metabolic dysfunction-associated steatotic liver disease). The project focuses on proactive healthcare using home testing and personalized health management.

news.cision.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Clinical validation partnership for the Egoo PHE testing system in children and adolescents with Phenylketonuria (PKU). The Birmingham study demonstrated high concordance between Egoo PHE Test results and Dry Blood Spot (DBS) reference methods. Results published in a peer-reviewed journal as a key milestone toward CE-mark submission and market launch.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-05
Description

Qlife and Hipro entered a non-binding Letter of Intent for a reverse takeover (announced June 2025). Nasdaq Stockholm AB rejected the initially contemplated 'Red Chip' structure in November 2025. LOI was extended to December 31, 2026 while alternative transaction structures are pursued. This would combine Qlife (listed shell) with Hipro's manufacturing and regulatory infrastructure.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-13
Description

Hipro assumes full responsibility for product development, regulatory submissions, manufacturing, and commercialization of Egoo in China. Qlife receives a 20% royalty on net sales generated from Egoo in China. Hipro has already implemented AI integration and user experience upgrades to the Egoo Q300 and plans to develop connectivity features enabling device-to-hospital communication. Strong interest from local hospitals in China is accelerating the process.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeDirect peer
Description

Abbott's diagnostics division (FreeStyle Libre for glucose monitoring, i-STAT for point-of-care) directly competes with Qlife in clinical-grade home and point-of-care biomarker testing, targeting the same chronic disease management customers with established FDA-cleared products.

TypeDirect peer
Description

Sinocare (including its PTS Diagnostics acquisition) is a direct competitor in point-of-care blood testing and consumer glucose monitoring, offering similar cartridge-based diagnostics and competing for pharmacy and home-use channels globally.

TypeDirect peer
Description

i-SENS (Caresens brand) is a Korean point-of-care and home diagnostics company producing blood glucose and HbA1c monitoring systems, directly comparable to Qlife's Egoo HbA1c cartridge-based platform in clinical accuracy and target use cases.

TypeDirect peer
Description

Trinity Biotech develops point-of-care and clinical laboratory diagnostic tests, including HbA1c measurement, and competes in similar hospital and decentralized testing channels as Qlife's Egoo platform.

TypeBroad incumbent
Description

Roche Diagnostics is a global IVD leader with extensive central lab and point-of-care offerings (cobas, Accu-Chek), competing broadly with Qlife across hospital, pharmacy, and home testing channels and serving as a benchmark for IVDR/FDA regulatory execution.

TypeBroad incumbent
Description

Siemens Healthineers operates a broad IVD portfolio including the Atellica and DCA Vantage point-of-care HbA1c analyzer, making it a broad incumbent competitor in decentralized hospital and clinic testing markets where Qlife is seeking adoption.

TypeBroad incumbent
Description

Bio-Rad is a diversified diagnostics and life science company with clinical diagnostics products including HbA1c testing, providing a broader competitive context in regulated IVD markets that Qlife's Egoo platform targets.

TypeBroad incumbent
Description

QuidelOrtho is a broad diagnostics company with point-of-care and laboratory testing products, overlapping with Qlife's decentralized testing strategy across hospitals, clinics, and pharmacy channels.

9Biofourmis
TypeEmerging player
Description

Biofourmis is a remote patient monitoring and virtual care platform focused on chronic disease management using biosensors and AI, comparable to Qlife's hospital-at-home and AI-driven personalized health ambitions for chronic disease monitoring.

TypeEmerging player
Description

Hinge Health applies AI-driven digital care to chronic conditions and is comparable to Qlife's AI-enabled personalized health management strategy, though focused on musculoskeletal conditions rather than blood biomarkers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qlife

Clinical Diagnostics / Home Medical Devicesqlifeholding.com

Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish medical technology company that develops the Egoo.Health platform — modular point-of-care blood biomarker testing devices and cartridges (HbA1c, PHE, hormones) with AI-driven insights — serving hospitals, pharmacies, and pharmaceutical partners across Europe, the US, and China via Hipro Biotechnology.

What Qlife does

Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish-incorporated medical technology company that develops and markets the Egoo.Health platform — a modular, decentralized blood biomarker testing system consisting of the Egoo Q300 portable reader, swap-in test cartridges (HbA1c for diabetes management, PHE for phenylketonuria monitoring, hormone panels for women's health), and the Egoo.AI software module that delivers text-based personalized health insights to patients and clinicians. The platform is designed to deliver clinical-grade precision outside central laboratories, with the HbA1c test achieving a coefficient of variation below 3% and the PHE test demonstrating high concordance with Dry Blood Spot reference methods in the Birmingham Women's and Children's NHS Foundation Trust clinical trial.

Qlife operates through its wholly-owned Danish subsidiary Egoo.Health ApS and serves three primary customer segments: healthcare providers and institutions (hospitals, NHS trusts), pharmaceutical and IVD companies (via feasibility and licensing deals), and pharmacies and retail health providers (via a Nordic pilot). The business model is multi-stream and pre-commercial at scale: direct sales of Egoo hardware and consumable cartridges, a 20% royalty on net sales of Egoo products in China where Hipro Biotechnology owns manufacturing, regulatory, and commercialization, exclusive EU/US distribution rights for Hipro's FDA-approved HbA1c test under a 20-year agreement, and non-dilutive feasibility study funding from global pharma partners. Reported revenue remains minimal — kSEK 21 in Q1 2026 against an EBITDA loss of kSEK -5,502 — consistent with a platform still in regulatory, clinical-validation, and partnership-build phases.

Qlife firmographics

Firmographics
Name
Qlife
Legal name
Qlife Holding AB
Website
https://qlifeholding.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Qlife Holding AB (Nasdaq First North Stockholm: QLIFE) is a Swedish medical technology company that develops the Egoo.Health platform — modular point-of-care blood biomarker testing devices and cartridges (HbA1c, PHE, hormones) with AI-driven insights — serving hospitals, pharmacies, and pharmaceutical partners across Europe, the US, and China via Hipro Biotechnology.
Ownership category
akta.pro rank

Qlife industry classification

Industry
Product category
Clinical Diagnostics / Home Medical Devices
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLALAFAL
Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAFAA
Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAPAA
Remote Patient Monitoring (RPM) Platforms & Services
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALABAF
Chronic Care & Remote Patient Monitoring (RPM) Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Home diagnostics
  • Point-of-care testing
  • Biomarker analysis
  • Decentralized diagnostics
  • Clinical blood testing

Where Qlife is headquartered

Location

Headquarters

HQ city
Værløse
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Qlife business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Egoo Platform Product Sales: Direct sales of Egoo.Health testing devices and consumable cartridges to healthcare providers, pharmacies, and consumers for home biomarker testing. Revenue generated from hardware sales and recurring consumable revenue in markets where regulatory approvals are in place.
  2. Licensing Royalties (China): Qlife receives a 20% royalty on net sales generated from Egoo products in China, where Hipro assumes full responsibility for development, regulatory approvals, manufacturing, and commercialization. This provides an asset-light revenue stream with no capital expenditure requirements.
  3. Distribution Revenue (EU/US - Hipro Products): Exclusive right to sell and distribute Hipro Biotechnology's products (including FDA-approved HbA1c test) in EU and US markets under a 20-year commercial agreement with automatic renewal. Qlife markets and distributes Hipro products integrated with or alongside the Egoo platform.
  4. Feasibility Study Funding: Fully funded feasibility agreements with global pharmaceutical companies to evaluate specific biomarker applications on the Egoo Health platform for therapeutic use cases. Funded entirely by the pharma partner, representing non-dilutive revenue for R&D activities.
  5. Partnership and Licensing Deals: Revenue from co-development and licensing arrangements with global IVD and pharmaceutical partners. Includes potential milestone payments, development fees, and long-term supply agreements as partnerships progress from feasibility to commercialization.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractRights Issue 2026 — SEK 2.0 per share

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Qlife product offering

Product offering

Core offering

Qlife develops and markets the Egoo.Health platform, a modular, decentralized blood biomarker testing system that enables clinical-grade diagnostics at home. The platform combines the portable Egoo Q300 analyzer with cartridge-based assays (HbA1c for diabetes management, PHE for phenylketonuria monitoring, and women's hormone panels) and AI-driven personalized insights delivered through device-to-cloud connectivity.

Product overview

Qlife develops and markets the Egoo.Health medical technology platform for clinical-grade home diagnostics. The platform architecture consists of the Egoo Q300 hardware device supporting multiple test cartridges/modules including the Egoo HbA1c (diabetes management), Egoo PHE System (phenylketonuria monitoring), Women's Health Platform (hormone testing), and the Egoo.AI module for AI-driven personalized insights. The modular platform enables decentralized biomarker testing at home with accuracy comparable to central laboratory testing.

Differentiator

Problem solved

Functional benefit

Brands

  • Egoo.Health: Medical technology platform for clinical-grade home diagnostics enabling biomarker testing at home
  • Egoo Phe system
  • Egoo HbA1c
  • Egoo.AI
  • Women's Health platform
  • Egoo Q300

Products and services

  • Egoo.Health Platform Clinical-grade medical technology platform for accurate biomarker testing at home. Uses a modular system that measures and analyses patient blood samples, enabling decentralized diagnostics for healthcare providers, pharmacies, pharma partners, and consumers.
  • Egoo Q300 Device Portable blood testing device with AI integration, device-to-cloud connectivity, and support for multiple biomarker cartridge tests. Designed for clinical-grade accuracy at home and in pharmacy settings.
  • Egoo HbA1c Blood Test Home-use HbA1c test cartridge for diabetes management achieving best-in-class precision with coefficient of variation below 3%. FDA-approved for the US market via the Hipro partnership.
  • Egoo PHE System Home testing system for Phenylketonuria (PKU) monitoring in children and adolescents. Validated through Birmingham Women's and Children's NHS Foundation Trust clinical trial; submitted for European IVDR regulatory approval.
  • Women's Health Platform Hormone testing platform with AI-driven personalized insights focused on women's reproductive and hormonal health, enabling proactive self-managed health monitoring at home.
  • Egoo.AI AI-driven personalized health insights module integrated into the Egoo Health platform, providing customized health recommendations and chronic disease management insights based on biomarker test results.

Quantifiable outcome

  • HbA1c coefficient of variation below 3% — best-in-class precision for home-use diabetes testing
  • +4 more outcomes

Companies that use Qlife

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Qlife technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Qlife partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Global Pharmaceutical Company (unnamed)coreStrategic or Co-development Partner · 1 June 2026Qlife entered a fully funded feasibility agreement with a global pharmaceutical company to evaluate a specific biomarker application on Egoo Health related to a therapeutic use case. The feasibility study is entirely funded by the pharma partner and is designed to answer technical and integration questions required to move into a long-term development and supply collaboration. The partner remains undisclosed.
  • Hipro Biotechnology Co., Ltd.coreStrategic or Co-development Partner · 16 December 2025Exclusive 20-year commercial agreement (with automatic renewal options) granting Qlife exclusive rights to distribute Hipro's products in the EU and US markets. Hipro has FDA approval for its HbA1c test (November 2024). The agreement includes integration of Hipro's FDA-approved HbA1c test with Qlife's Egoo platform, aiming to develop decentralized healthcare solutions. Separately, Qlife and Hipro pursued a reverse takeover (Nasdaq rejected the 'Red Chip' structure in November 2025; alternative structures being explored; LOI extended to December 31, 2026).
  • Beijing Tsinghua Changgung HospitalminorStrategic or Co-development Partner · 12 December 2025Collaboration led by Hipro Biotechnology in China for an AI-driven personalized diabetes management project. Egoo Health blood testing platform is used for chronic disease management of diabetes and MASLD (metabolic dysfunction-associated steatotic liver disease). The project focuses on proactive healthcare using home testing and personalized health management.
  • Birmingham Women's and Children's NHS Foundation TrustcoreStrategic or Co-development Partner · 5 November 2025Clinical validation partnership for the Egoo PHE testing system in children and adolescents with Phenylketonuria (PKU). The Birmingham study demonstrated high concordance between Egoo PHE Test results and Dry Blood Spot (DBS) reference methods. Results published in a peer-reviewed journal as a key milestone toward CE-mark submission and market launch.
  • Hipro Biotechnology Co., Ltd. (Reverse Takeover)coreStrategic or Co-development Partner · 5 June 2025Qlife and Hipro entered a non-binding Letter of Intent for a reverse takeover (announced June 2025). Nasdaq Stockholm AB rejected the initially contemplated 'Red Chip' structure in November 2025. LOI was extended to December 31, 2026 while alternative transaction structures are pursued. This would combine Qlife (listed shell) with Hipro's manufacturing and regulatory infrastructure.
  • Hipro Biotechnology Co., Ltd. (China Operations)coreTechnology or Integration · 13 March 2025Hipro assumes full responsibility for product development, regulatory submissions, manufacturing, and commercialization of Egoo in China. Qlife receives a 20% royalty on net sales generated from Egoo in China. Hipro has already implemented AI integration and user experience upgrades to the Egoo Q300 and plans to develop connectivity features enabling device-to-hospital communication. Strong interest from local hospitals in China is accelerating the process.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Qlife competitors and assessment

Company assessment

Direct peers

  • Abbott: Abbott's diagnostics division (FreeStyle Libre for glucose monitoring, i-STAT for point-of-care) directly competes with Qlife in clinical-grade home and point-of-care biomarker testing, targeting the same chronic disease management customers with established FDA-cleared products.
  • Sinocare: Sinocare (including its PTS Diagnostics acquisition) is a direct competitor in point-of-care blood testing and consumer glucose monitoring, offering similar cartridge-based diagnostics and competing for pharmacy and home-use channels globally.
  • i-SENS: i-SENS (Caresens brand) is a Korean point-of-care and home diagnostics company producing blood glucose and HbA1c monitoring systems, directly comparable to Qlife's Egoo HbA1c cartridge-based platform in clinical accuracy and target use cases.
  • Trinity Biotech: Trinity Biotech develops point-of-care and clinical laboratory diagnostic tests, including HbA1c measurement, and competes in similar hospital and decentralized testing channels as Qlife's Egoo platform.

Broad incumbents

  • Roche Diagnostics: Roche Diagnostics is a global IVD leader with extensive central lab and point-of-care offerings (cobas, Accu-Chek), competing broadly with Qlife across hospital, pharmacy, and home testing channels and serving as a benchmark for IVDR/FDA regulatory execution.
  • Siemens Healthineers: Siemens Healthineers operates a broad IVD portfolio including the Atellica and DCA Vantage point-of-care HbA1c analyzer, making it a broad incumbent competitor in decentralized hospital and clinic testing markets where Qlife is seeking adoption.
  • Bio-Rad Laboratories: Bio-Rad is a diversified diagnostics and life science company with clinical diagnostics products including HbA1c testing, providing a broader competitive context in regulated IVD markets that Qlife's Egoo platform targets.
  • QuidelOrtho: QuidelOrtho is a broad diagnostics company with point-of-care and laboratory testing products, overlapping with Qlife's decentralized testing strategy across hospitals, clinics, and pharmacy channels.

Emerging players

  • Biofourmis: Biofourmis is a remote patient monitoring and virtual care platform focused on chronic disease management using biosensors and AI, comparable to Qlife's hospital-at-home and AI-driven personalized health ambitions for chronic disease monitoring.
  • Hinge Health: Hinge Health applies AI-driven digital care to chronic conditions and is comparable to Qlife's AI-enabled personalized health management strategy, though focused on musculoskeletal conditions rather than blood biomarkers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Qlife social profiles

Digital presence

Qlife compliance and trust

Trust signal

Compliance2 records

Qlife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qlife leadership team

Management profile

Number of profiles

Profiles5 records

Qlife subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Qlife funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qlife M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qlife

What does Qlife do?

Qlife develops and markets the Egoo.Health platform, a modular, decentralized blood biomarker testing system that enables clinical-grade diagnostics at home. The platform combines the portable Egoo Q300 analyzer with cartridge-based assays (HbA1c for diabetes management, PHE for phenylketonuria monitoring, and women's hormone panels) and AI-driven personalized insights delivered through device-to-cloud connectivity.

Is Qlife a public or private company?

Qlife is a public company. It is classified as public and is currently operating.

When was Qlife founded?

Qlife was founded in 2019. It employs 1 to 10 people.

Where is Qlife based?

Qlife is headquartered in Værløse, Denmark, in the Europe region.

How does Qlife make money?

Five revenue lines are on record. Egoo Platform Product Sales are the primary driver. The others are licensing Royalties (China), distribution Revenue (EU/US - Hipro Products), feasibility Study Funding and partnership and Licensing Deals.

Who are Qlife's main competitors?

Direct peers on record are Abbott, Sinocare, i-SENS and Trinity Biotech. Broad incumbents are Roche Diagnostics, Siemens Healthineers, Bio-Rad Laboratories and QuidelOrtho. Emerging players are Biofourmis and Hinge Health.

Does Qlife have an API?

No public API is recorded for Qlife.

What industry is Qlife in?

Qlife's product category is Clinical Diagnostics / Home Medical Devices. Its primary akta.pro industry code is HLALAFAL, Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management), with a secondary code of HLACAFAA, Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingNotice of Extraordinary General Meeting in Qlife Holding ABQlife Holding AB's shareholders are invited to an extraordinary general meeting on 1 December 2026 to approve a directed issue of up to 3,774,806 shares and 1,887,403 warrants. The subscription price is SEK 0.93, a discount of about 0.5% from the ten-day VWAP, with warrants exercisable at SEK 1.86.news.cision.comNotice of Extraordinary General Meeting in Qlife Holding ABQlife Holding AB will hold an extraordinary general meeting on 1 December 2026 to approve a directed issue of up to 3,774,806 shares and 1,887,403 warrants. The subscription price is SEK 0.93 per share, a discount of about 0.5% from the ten-day VWAP, with warrants issued free of charge.Dealroom.coQlife raises $773,000 in directed share issue, with $350K more proposed | Dealroom NewsQlife raised $773,000 in a directed share issue, with $350,000 more proposed, to fund its Egoo at-home testing platform. The capital supports its business plan through 2027 and a potential larger development program with a global pharmaceutical partner. The company reported $229,700 in cash at Q3 end and no quarterly revenue.The future of tradingQlife Holding Announces Extraordinary General MeetingQlife Holding announced an extraordinary general meeting on December 1, 2026, to consider a SEK 3.5 million directed issue by JEQ Capital. The proposal covers 3,774,806 shares at SEK 0.93 each, with warrants, and would dilute existing holdings by approximately 9.2%.The future of tradingQlife carries out a directed issue of approx. SEK 7.7 million and a shareholder proposes a directed issue of approx. SEK 3.5 millionQlife Holding AB's board resolved a directed issue of shares and warrants for approximately SEK 7.7 million, with all shares and warrants subscribed. A shareholder, JEQ Capital, proposed a directed issue of about SEK 3.5 million to board members and management. The company expects to use proceeds for preparations for a potential transition into a larger development program.news.cision.comQlife carries out a directed issue of approx. SEK 7.7 million and a shareholder proposes a directed issue of approx. SEK 3.5 millionQlife Holding AB's board resolved a directed issue of approximately SEK 7.7 million in shares and warrants, with all subscriptions completed. A shareholder, JEQ Capital, proposed a directed issue of about SEK 3.5 million to board members and consultants, to be voted on at an extraordinary general meeting on 1 December 2026.The future of tradingQlife Q3 net loss narrows 44% to SEK 3.93 millionQlife Holding's third-quarter 2026 net loss narrowed 44% year over year to SEK 3.93 million, with revenue falling to none from SEK 65,000 and total cash flow turning negative at SEK 2.8 million. The company is entering a product-readiness phase with its pharmaceutical partner, backed by SEK 2.7 million in partner funding.news.cision.comQLIFE HOLDING AB, Interim Report Q3, July - September 2026Qlife Holding AB reported Q3 2026 revenue of kSEK 0 and a net loss of kSEK 3,932. The company entered a partner-financed product-readiness phase with a pharmaceutical partner, funded by SEK 2.7 million, and received USPTO patent approval and ISO 13485 certification for its Egoo platform.news.cision.comQlife receives ISO 13485 certification specifically covering at-home testing for Phenylalanine (PHE)Qlife received ISO 13485 certification for its at-home blood testing solution for phenylalanine, covering the Phenylketonuria condition. The certification validates its quality management system and supports its regulatory strategy, including CE marking under EU IVDR. CEO Thomas Warthoe said it lays the foundation for future biomarker partnerships.The future of tradingQlife wins US patent approval for core Egoo platform technologyQlife Holding AB secured U.S. patent approval for core technology behind its Egoo decentralized biomarker-testing platform, covering integrated sample mixing and optical measurement in a compact, automated system. Management framed the U.S. intellectual-property position as a strategic boost for partnering talks, alongside existing protection in Europe and China. The patent is expected to be formally issued once final USPTO administrative steps are completed.